Thalassemia Reports | Free Full-Text | CRISPR Gene Therapy: A Promising One-Time Therapeutic Approach for Transfusion-Dependent β-Thalassemia—CRISPR-Cas9 Gene Editing for β-Thalassemia
CarrierMax™ SMN1/SMN2 Reagent Kit
VEGF121b, a new member of the VEGFxxxb family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo | British Journal of Cancer
NEMO Links Nuclear Factor-κB to Human Diseases: Trends in Molecular Medicine
Dr Gaetan Burgio @gaetan_burgio@mstdn.science on Twitter: "So they investigate this and found vasa promoter has significant somatic resistance -> Do not design a drive under Vasa !!!! & they found resistance occurs